Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Short term Debt (2016 - 2022)

Historic Short term Debt for Lexaria Bioscience (LEXX) over the last 12 years, with Q2 2022 value amounting to $7906.0.

  • Lexaria Bioscience's Short term Debt rose 531.5% to $7906.0 in Q2 2022 from the same period last year, while for May 2022 it was $7906.0, marking a year-over-year increase of 531.5%. This contributed to the annual value of $7926.0 for FY2021, which is 8649.84% down from last year.
  • Lexaria Bioscience's Short term Debt amounted to $7906.0 in Q2 2022, which was up 531.5% from $7875.0 recorded in Q1 2022.
  • Lexaria Bioscience's 5-year Short term Debt high stood at $206806.0 for Q1 2021, and its period low was $1600.0 during Q1 2020.
  • Moreover, its 5-year median value for Short term Debt was $9110.0 (2018), whereas its average is $33730.9.
  • Its Short term Debt has fluctuated over the past 5 years, first plummeted by 9802.06% in 2018, then surged by 1282537.5% in 2021.
  • Over the past 5 years, Lexaria Bioscience's Short term Debt (Quarter) stood at $21654.0 in 2018, then soared by 71.79% to $37200.0 in 2019, then surged by 134.37% to $87185.0 in 2020, then tumbled by 91.03% to $7817.0 in 2021, then rose by 1.14% to $7906.0 in 2022.
  • Its Short term Debt stands at $7906.0 for Q2 2022, versus $7875.0 for Q1 2022 and $7817.0 for Q4 2021.